Three pharmaceutical companies are launched to develop generic drugs of Iressa which costs about 30 billion won

Three domestic pharmaceutical companies are being competitive for the development generic lung cancer drug.

On 29th according to MFDS, there are three generic developing companies which have passed bioequivalence Test(BE Test) for gefinitib

Gefinitib is a main component of Iressa, and CKD, Ildong and Hanmi have been launched to develop the generics.

Iressa is the lung cancer drug that is dev...